Wednesday 29 July 2015, Amsterdam
The report recognizes the following companies as the key players in the Global Ischemic Heart Disease Drugs Market: AstraZeneca plc, Bayer AG, Eli Lilly and Co., Novartis AG, Pfizer Inc. and Sanofi SA
Commenting on the report, an analyst said: “The market has huge growth opportunities for vendors because of the growing population of individuals with IHD. To capture maximum market shares and expand the focus area, vendors are investing more on R&D.”
According to the report, the high prevalence of chronic conditions such as hypertension, diabetes, and cholesterol levels are leading to an increase in cardiovascular diseases. The people with diabetes are three to four times more likely to develop CVDs than people without diabetes.
Further, the report states that the availability of effective surgical treatments and the use of catheter based interventions pose a challenge to the growth of market. The need for specific therapeutics at the later stages of the disease leads to the increased reliance on stents and surgeries.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
ASDReports.com Media contact: S. Koopman -
Marketing and Communications
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : firstname.lastname@example.org
back to News